Curis (NASDAQ:CRIS) Receives “Buy” Rating from HC Wainwright

Curis (NASDAQ:CRIS)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $20.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 406.33% from the stock’s previous close.

Curis Trading Down 0.8 %

Shares of CRIS stock opened at $3.95 on Friday. The company has a market capitalization of $23.62 million, a P/E ratio of -0.51 and a beta of 3.35. Curis has a 12 month low of $3.51 and a 12 month high of $17.49. The stock has a 50 day moving average of $5.01 and a two-hundred day moving average of $7.12.

Institutional Investors Weigh In On Curis

Several institutional investors and hedge funds have recently bought and sold shares of CRIS. Focused Wealth Management Inc lifted its holdings in shares of Curis by 63.1% during the 3rd quarter. Focused Wealth Management Inc now owns 54,066 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 20,908 shares during the period. Point72 Asset Management L.P. raised its position in Curis by 795.5% in the second quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock worth $748,000 after purchasing an additional 96,256 shares in the last quarter. CM Management LLC lifted its stake in Curis by 380.0% during the first quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock worth $1,304,000 after purchasing an additional 95,000 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in Curis by 4.8% during the first quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock valued at $2,376,000 after purchasing an additional 10,097 shares in the last quarter. Institutional investors own 29.97% of the company’s stock.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.